Management of Acne Vulgaris With Trifarotene.
J Cutan Med Surg
; 27(4): 368-374, 2023.
Article
em En
| MEDLINE
| ID: mdl-36927117
ABSTRACT
Topical retinoids have an essential role in treatment of acne. Trifarotene, a topical retinoid selective for retinoic acid receptor (RAR) γ, is the most recent retinoid approved for treatment of acne. RAR-γ is the most common isoform of RARs in skin, and the strong selectivity of trifarotene for RAR-γ translates to efficacy in low concentration. Trifarotene, like other topical retinoids, acts by increasing keratinocyte differentiation and decreasing proliferation, which reduces hyperkeratinization. Retinoids have also been shown to inhibit inflammatory pathways via effects on leukocyte migration, toll-like receptors, and Activator Protein (AP)-1. Large-scale randomized, controlled clinical trials have demonstrated trifarotene to be safe, well tolerated, and efficacious in reducing both comedones and papules/pustules of acne. However, unlike all other retinoids, trifarotene is the first topical retinoid with rigorous clinical data on safety and efficacy in truncal acne. Data supporting use of trifarotene to manage acne are reviewed in this publication.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Acne Vulgar
/
Fármacos Dermatológicos
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
J Cutan Med Surg
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Canadá